Colorectal SACT regimens:

Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment. Check the regimen details for the specific indication the regimen may be used / funded in. See our disclaimer.

Anal Metastatic

• Cisplatin Capecitabine
• Cisplatin Fluorouracil (CF75)
• Mitomycin Capecitabine with concurrent RT
• Mitomycin Fluorouracil with concurrent RT 

Colon Adjuvant 

• Capecitabine
• Oxaliplatin Capecitabine (CapOx)
• Oxaliplatin Modified de Gramont (FolFOx)
• Irinotecan Oxaliplatin Modified de Gramont modified (FolFOxIri modified) (neoadjuvant) (local funding)

Colon Metastatic

• Capecitabine
• Cetuximab Encorafenib
• Cetuximab Irinotecan Modified de Gramont (Cetuximab FolFIri)
• Cetuximab Irinotecan Oxaliplatin Modified de Gramont (Cetuximab FolFOxIri)
• Cetuximab Oxaliplatin Modified de Gramont (Cetuximab FolFOx)
• Fruquintinib – requires CQG approval
• Ipilimumab Nivolumab (had previous fluorouracil treatment)
• Ipilimumab Nivolumab (previously untreated) – requires CQG approval
• Irinotecan
• Irinotecan Modified de Gramont (FolFIri)
• Irinotecan Oxaliplatin Modified de Gramont (FolFOxIri) (metastatic)
• Mitomycin Capecitabine
• Modified de Gramont
• Oxaliplatin Capecitabine (CapOx)
• Oxaliplatin Modified de Gramont (FolFOx)
• Panitumumab Irinotecan Modified de Gramont (Panitumumab FolFIri)
• Panitumumab Oxaliplatin Modified de Gramont (Panitumumab FolFOx)
• Pembrolizumab
• Raltitrexed
• Raltitrexed Oxaliplatin
• Regorafenib
• Trifluridine-tipiracil
• Trifluridine-tipiracil Bevacizumab

Rectal Adjuvant

• Capecitabine
• Oxaliplatin Capecitabine (CapOx)
• Oxaliplatin Modified de Gramont (FolFOx)
• Irinotecan Oxaliplatin Modified de Gramont modified (FolFOxIri modified) (neoadjuvant) (local funding)

Rectal Metastatic

• Capecitabine
• Capecitabine with concurrent RT
• Cetuximab Encorafenib
• Cetuximab Irinotecan Modified de Gramont (Cetuximab FolFIri)
• Cetuximab Irinotecan Oxaliplatin Modified de Gramont (Cetuximab FolFOxIri)
• Cetuximab Oxaliplatin Modified de Gramont (Cetuximab FolFOx)
• Fruquintinib – requires CQG approval
• Ipilimumab Nivolumab (had previous fluorouracil treatment)
• Ipilimumab Nivolumab (previously untreated) – requires CQG approval
• Irinotecan
• Irinotecan Modified de Gramont (FolFIri)
• Irinotecan Oxaliplatin Modified de Gramont (FolFOxIri) (metastatic)
• Mitomycin Capecitabine
• Modified de Gramont
• Oxaliplatin Capecitabine (CapOx)
• Oxaliplatin Modified de Gramont (FolFOx)
• Panitumumab Irinotecan Modified de Gramont (Panitumumab FolFIri)
• Panitumumab Irinotecan Oxaliplatin Modified de Gramont (Panitumumab FolFOxIri) – archived
• Panitumumab Oxaliplatin Modified de Gramont (Panitumumab FolFOx)
• Pembrolizumab
• Raltitrexed
• Raltitrexed Oxaliplatin
• Regorafenib
• Trifluridine-tipiracil
• Trifluridine-tipiracil Bevacizumab

SACT regimens written by S Coutts

For further information please contact us using our contact us page